Publication:
Breast cancer and combined oral contraceptives: Results from a multinational study

dc.contributor.authorGeoffrey Berryen_US
dc.contributor.authorRobert MacLennanen_US
dc.contributor.authorRodney Shearmanen_US
dc.contributor.authorTatiana Jelihovskyen_US
dc.contributor.authorJoan Cooper Boothen_US
dc.contributor.authorRamiro Molinaen_US
dc.contributor.authorLuis Martinezen_US
dc.contributor.authorOriana Salasen_US
dc.contributor.authorAlfredo Dabancensen_US
dc.contributor.authorChen Zhihengen_US
dc.contributor.authorTao Yunen_US
dc.contributor.authorHu Yong Weien_US
dc.contributor.authorAlvaro Cuadrosen_US
dc.contributor.authorNubia Aristizabalen_US
dc.contributor.authorK. Ebelingen_US
dc.contributor.authorP. Nishanen_US
dc.contributor.authorD. Kundeen_US
dc.contributor.authorBaruch Modanen_US
dc.contributor.authorElaine Ronen_US
dc.contributor.authorEster Alfandaryen_US
dc.contributor.authorJ. G. Matien_US
dc.contributor.authorPatrick Kenyaen_US
dc.contributor.authorAlfred Kunguen_US
dc.contributor.authorD. Gateien_US
dc.contributor.authorHector Rodriguez Cuevasen_US
dc.contributor.authorSocorro Benavides Salazaren_US
dc.contributor.authorAntonio Paleten_US
dc.contributor.authorPatricia Ontiverosen_US
dc.contributor.authorRuben A. Apeloen_US
dc.contributor.authorJulietta R. de la Cruzen_US
dc.contributor.authorJose Baensen_US
dc.contributor.authorBenita Javieren_US
dc.contributor.authorSuporn Silpisornkosolen_US
dc.contributor.authorTieng Pardthaisongen_US
dc.contributor.authorNimit Martinen_US
dc.contributor.authorChoti Theetranonten_US
dc.contributor.authorBanpot Boosirien_US
dc.contributor.authorSupawat Chutivongseen_US
dc.contributor.authorPramuan Virutamasenen_US
dc.contributor.authorChansuda Wongsrichanalaien_US
dc.contributor.authorPrasarn Jimakornen_US
dc.contributor.authorSuporn Koetsawangen_US
dc.contributor.authorDaungdao Rachawaten_US
dc.contributor.authorNivat Chantarakulen_US
dc.contributor.authorHelge Stalsbergen_US
dc.contributor.authorDavid B. Thomasen_US
dc.contributor.authorElizabeth A. Noonanen_US
dc.contributor.authorSusan Holcken_US
dc.contributor.otherThe University of Sydneyen_US
dc.contributor.otherFacultad de Medicina de la Universidad de Chileen_US
dc.contributor.otherShanghai Institute of Planned Parenthood Researchen_US
dc.contributor.otherHospital Universitarioen_US
dc.contributor.otherAkademie der Wissenschaften der DDRen_US
dc.contributor.otherChaim Sheba Medical Center Israelen_US
dc.contributor.otherUniversity of Nairobien_US
dc.contributor.otherHospital General de Mexicoen_US
dc.contributor.otherUniversity of the Philippines Manilaen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversitetet i Tromsoen_US
dc.contributor.otherFred Hutchinson Cancer Research Centeren_US
dc.contributor.otherOrganisation Mondiale de la Santeen_US
dc.contributor.otherHospital del Salvadoren_US
dc.date.accessioned2018-06-14T09:20:37Z
dc.date.available2018-06-14T09:20:37Z
dc.date.issued1990-01-01en_US
dc.description.abstractA collaborative, hospital-based case-control study was conducted at 12 participating centres in 10 countries. Based on data from personal interviews of 2, 116 women with newly diagnosed breast cancer and 12,077 controls, the relative risk of breast cancer in women who ever used oral contraceptives was estimated to be 1.15 (1.02, 1.29). Estimated values of this relative risk based on data from three developed and seven developing countries were 1.07 (0.91, 1.26) and 1.24 (1.05, 1.47) respectively; these estimates are not significantly different (P = 0.22). Estimates for women under and over age 35 were 1.26 (0.95, 1.66) and 1.12 (0.98, 1.27), respectively, and these estimates are also not significantly different (P= 0.38). Risk was highest in recent and current users and declined with time since last use regardless of duration of use. Risk did not increase with duration of use after stratifying on time since last use. Risk did not increase significantly with increasing duration of use before age 25 or before a first live birth. However, a relative risk of 1.5 that was of borderline statistical significance was observed in women who used oral contraceptives for more than 2 years before age 25. No single source of bias or confounding was identified that could explain the small increases in risk that were observed. Chance alone is also an unlikely explanation. The results could be due to a combination of chance and potential sources of bias, or they could represent a weak causal relationship. © Macmillan Press Ltd., 1990.en_US
dc.identifier.citationBritish Journal of Cancer. Vol.61, No.1 (1990), 110-119en_US
dc.identifier.doi10.1038/bjc.1990.23en_US
dc.identifier.issn15321827en_US
dc.identifier.issn00070920en_US
dc.identifier.other2-s2.0-0025044624en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/15930
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0025044624&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleBreast cancer and combined oral contraceptives: Results from a multinational studyen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0025044624&origin=inwarden_US

Files

Collections